Each month, GHEA aggregates the latest news and research related to place-based cancer control and geographic health disparities. Below you will find the latest posts, updated regularly throughout the month.
(Last updated: July 22, 2021)
Place-Based Cancer Control News and Research
- A new report from a recent CDC Morbidity and Mortality Report shows there is a lower reduction in cancer death rates in rural America (a decrease of 1.0 percent per year) compared with urban America (a decrease of 1.6 percent per year).
General Cancer Control News and Research
- A study on the effects of the COVID-19 pandemic on cancer detection and surgical treatments finds a 10.2 percent decline in pathology reports from population-based cancer registries in 2020 compared with those in 2019.
- The FDA has recently approved Phesgo, an at-home treatment for patients with early HER2-positive breast cancer or those where the cancer has spread to other parts of the body.
- Researchers find that antiandrogen enzalutamide, a drug typically used to treat prostate cancer, could be explored for treating patients with COVID-19.
- A study finds that more than nine out of 10 cancer patients showed good immune response to the COVID-19 mRNA vaccines after receiving both doses, however, a subset of high-risk patients did not.
- Researchers examining COVID-19’s impact on CDC’s National Breast and Cervical Cancer Early Detection Program (NBCCEDP) funded cancer screening services found the total number of NBCCEDP-funded breast and cervical cancer screening tests declined by 87 percent and 84 percent, respectively, during April 2020.
- New research suggests that individuals, especially those under the age of 50 years, may be at an increased risk of colon cancer due to the use of antibiotics.
- Researchers discover that hematopoietic stem cells make use of RNA molecules from “junk DNA” sections to enhance their activation after chemotherapy.
- A research study identifies how the pharmacological activation of the protein p53 boosts the immune response against tumors. These results can support the development of new combination therapies that could give more cancer patients access to immunotherapy.
